Method for the treatment of psoriatic arthritis

 

(57) Abstract:

The invention relates to medicine, and is intended for the treatment of psoriatic arthritis. Background drug therapy on the affected joint influence of the magnetic field with induction on the surface of the body 60-70 MT, educated magnetic system consisting of two magnets plate form, located at the junction interface in the same plane and facing each other and the workpiece surface opposite poles. The magnetic field is conducted in a circular motion clockwise with a speed of 2-3 cm/s for 2-3 min, in the course of 10-12 treatments. The method allows to increase the effectiveness of the treatment of psoriatic arthritis. 2 C.p. f-crystals.

The invention relates to medicine, namely to physical therapy and dermatology, and relates to methods of treatment of psoriatic arthritis.

There is a method of treatment of psoriatic arthritis, including the effects of anti-inflammatory, antihistamine, giposensibiliziruyuschey, sedatives, adaptogenes, vitamins, bio-stimulants, local therapy, medicines and betatron [1].

The disadvantage of this method is the long duration of the treatment is WMD method is a method of treating psoriatic arthritis, including the appointment of an anti-inflammatory, antihistamine, giposensibiliziruyuschey, sedatives, adaptogenes, vitamins, bio-stimulants, local therapy and the use of the betatron [2].

However, the use of betatron therapy has several limitations, maintenance betatron difficult and expensive, the treatment time is long, make 3-4 weeks, which limits the application of this type of physiotherapy treatment.

The problem solved by this invention is the reduction of treatment time and the extension of the scope of the method.

The problem is solved by assigning medical therapy with simultaneous impact on the affected joint magnetic field with induction 60-70 MT, educated magnetic system consisting of two magnets plate form, located at the junction interface in the same plane and facing each other and the workpiece surface opposite poles that move in a circular motion clockwise with a speed of 2-3 cm per second for 2-3 minutes over the course of 10-12 treatments.

The authors are not found in the analysed literature distinguishing features of the proposed method and the Siberian medical University. Thus, this solution meets the criteria of the invention: "novelty", "inventive step" and "capable of industrial application".

A method of treating psoriatic arthritis is as follows. The patient is prescribed medical therapy, including the use of antihistamines, giposensibiliziruyuschey, sedatives, adaptogenes, vitamins, bio-stimulants, local therapy with simultaneous conduction of magnetic therapy.

Magnetic therapy is used from the first day of treatment and carry out as follows: the patient is in the sitting position. Procedures carried out daily, in the course of 10-12 treatments. Magnetic system with induction on the surface of the body 60-70 MT, formed by two plate magnets form, located at the junction interface in the same plane and facing each other and the workpiece surface opposite poles that move in a circular motion clockwise with a speed of 2-3 cm per second for 2-3 minutes.

Example

Patient Aspen L. K., 45 years of age, was treated at the clinic of skin diseases, Siberian medical University, history N 5985. The diagnosis at admission to the hospital: psoriasis vulgaris, Nummela the Orme, the high level of activity.

Complaints received at a scaly rash bright red color on the skin of the scalp, trunk and extremities. In addition, bothered by pain in the interphalangeal and metatarsophalangeal joints V and IV fingers of the left foot, resulting in movement and physical activity, swelling and redness.

From the anamnesis: the first appearance of skin rash began to disturb the patient since 1995, when the skin of the scalp after a nervous overstrain appeared scaly bright red rash. When viewed from the dermatologist and was diagnosed with psoriasis. A year later similar lesions appeared on the skin of the trunk and limbs.

Through the year, in addition to the skin rash, the patient began to disturb pains in the joints V and IV fingers on the left and IV and III of the toes of the right foot, and second finger of the right hand.

With this period of time the patient notes annual exacerbation of cutaneous and articular processes, regardless of the time of year.

Admission: General condition is satisfactory, mucous membranes clean, damp. Heart sounds are clear, rhythmic, pulse - 72 tank/min, blood pressure of 120/75 mm RT. Art.

Status local color papules and plaques sharply infiltrated. On the surface of psoriatic efflorescence noted melkopuzyrchatoy peeling with silvery-white color, located in the center of the elements, the periphery of the lesions in the form of narrow bezel red free from peeling. Detected positive psoriatic triad.

During the inspection of the joints revealed a sharp hyperemia, edema interphalangeal and metatarsophalangeal joints V and IV fingers of the left foot. During passive and active movements, as well as palpation in these joints have seen a sharp pain.

The studies were conducted

Duodenal intubation: a portion of the a - 30 ml, light yellow color, transparent, leukocytes - 3-5, epithelial cells 10-15 in sight, corn starch - 0-1. Portion 60 ml, light yellow, transparent, leukocytes - 2-5, epic. cells in large quantities. Portion With 20 ml, light yellow, cloudy, leukocytes to 10, epit. cells 10-15 in the field of view, mucus. Eggs of opisthorchis not found.

Ultrasound examination of abdominal cavity organs. Conclusion: signs of chronic cholecystitis, pyelonephritis. Nephroptosis on the right. Diffuse changes of pancreatic tissue.

Esophagogastroduodenoscopy. Conclusion: focal ser (0,89), LED3 T-limp. - 64 (1,26), CD8 T-PMPs. - 37 (0,73), CD4 T-help. - 32 (0,63), SD the N - 21 (0,41), IgG and 7.6 mg/ml, IgA - 4,2, IgM - 3.2, Netspot. - 14%, Ststem. - 39. Conclusion: In-lymphocytosis with elevated levels of IgM. Increased number of CD8 lymphocytes and PC-cells - stimulation of the cellular link or system.

OAK: HB 120 g/l, ESR - 6 mm/h, WBC 4.8 g/l, erythrocytes - 3,6, eosinophila - 2%, lymphocytes - 34, monocytes - 3, segmented neutrophils - 55.

Blood biochemistry: blood glucose - 6.5 mmol/l, bilirubin - 14.0 mmol/l, CRP - negative, urea - 6.5 mmol/l, amylase - 24 g/CL, thymol test -1,7%, seromukoidy - 0,24%

The treatment was carried out as follows: was assigned to drug therapy: suprastin 1 tablet 2 times a day for 15 days, pills Valerian to 23 times a day - 15 days, capsules aevit to 22 times a day on the course of 1 month, vitamin B1 at 1 mlm N 10, vitamin B6 and 1 mlm N 10, the ascorbic acid solution 5% at 1 mlm N 10, a solution of nicotinic acid 1% 1ml in m N 10, the solution of aloe extract inm 1 ml N 10, locally 2% salicylic ointment. Also was appointed magnetotherapy.

Magnetic therapy was used with the first day of treatment and was administered as follows: the patient was in a sitting position. Procedures were performed daily,bsem the basis of a joint in a joint permanent magnets facing to each other and to the body opposite poles, moved in a circular motion clockwise with a speed of 3 cm per second for 3 minutes.

The reduction in pain was observed after the 3-s procedures and to the beginning of the 10 treatments of pain in the joints completely stopped. Redness of the affected joints began to decrease after the 2nd procedure, completely disappeared after 5 treatments. Periarticular swelling of the tissues began to decrease after 4 treatments and completely disappeared after 9 treatments.

After a full course of magnetotherapy subjective complaints of the patient and objective changes in the affected joints were not found.

At discharge: cutaneous manifestations of psoriasis corresponded to the regressive stage of the disease, subjective complaints of the patient and any objective data for the defeat of the joints was not found.

The rationale. Use in the treatment field of the magnetic system consisting of two magnets plate form, located at the junction interface in the same plane and facing the workpiece surface and to each other unlike poles, allows you to create non-uniform in direction and the magnetic field with a pronounced gradient in the direction. With three peonim magnetic field in the damage zone. These features devices and methods of treatment lead to improved efficiency of magnetised.

Use as physiotherapy factor above the magnetic system and labile methods of magnetic field makes the treatment process is practically safe. For treatment is not required in the equipment Cabinet, the application of remedies.

The simultaneous influence of a magnetic field allows to exclude from complex drugs anti-inflammatory agents, which reduces the likelihood of undesirable side reactions. This is achieved by the increase in magnetic therapy reserve capacity of the body.

The selected stimulation modes are for the reason that the reduction in the duration of one procedure and term impacts will not provide the necessary long-lasting positive effects from the magnetic therapy, and prolonged periods is not advisable for the reason that required sustained therapeutic effect achieved by the claimed conditions.

The advantages of the proposed method consist in the reduction of treatment time, the possibility of its use for any e is TLAT effects in the treatment of psoriatic arthritis other medication therapeutic factors

Furthermore, the method with the inclusion of magnetic therapy has the following effects: anti-inflammatory, anti-inflammatory, analgesic, desensitizing, and also normalizes the peripheral circulation.

The method can be used in inpatient and outpatient settings. He Ayvazian, simple, does not cause adverse reactions. For its implementation does not require special conditions, expensive equipment.

Sources of information

1. Zuev A. C. Betacarotene in the treatment of patients with psoriatic arthritis //Act. the matters. sovr. medicine, I. 2; proc. Dokl. VII scientific and practical. conference of physicians. - Novosibirsk. - 1997.- C. 336-337.

2. Zuev A. C. the Results of betacarotene in the complex treatment of patients with psoriatic arthritis //Act. the matters. a resort. and physiotherap.: Matera, ubil. scientific-practical. conference Netif. - Tomsk. - 1997.- C. 204-205.

3. Milevsky, S. Diagnosis and treatment of psoriatic arthritis (methodical recommendations)..." /Tomsk. 1991. - S. 20.

1. Method for the treatment of psoriatic arthritis by assigning drug therapy, characterized in that on the background of drug therapy on the affected joint influence of the magnetic field with inductee is, located at the junction interface in the same plane and facing each other and the workpiece surface opposite poles.

2. A method of treating psoriatic arthritis under item 1, characterized in that the magnetic field is carried out in 2-3 minutes, at the rate of 10-12 procedures.

3. A method of treating psoriatic arthritis under item 1, characterized in that the magnetic field is conducted in a circular motion clockwise with a speed of 2-3 cm/S.

 

Same patents:

The invention relates to medicine, and is intended for the treatment of chronic adnexitis

The invention relates to medical equipment, namely, magnetic therapy, and is intended for the treatment of many diseases, including gastrointestinal - liver cirrhosis with portal hypertension and splenomegaly, chronic hepatitis, cholecystitis and cholelithiasis, pancreatitis, peptic ulcer and 12 duodenal ulcer; urological diseases, pyelonephritis, urolithiasis, the implementation of regeneration nonfunctioning kidneys, etc

The invention relates to medical equipment, namely, magnetic therapy, and can be used in the treatment of many diseases, including cirrhosis of the liver complicated forms in the course of regeneration of dysfunctional organs, the treatment of BPH, provides painless crushing and output concretions of various organs, treats mastitis and fibroadenoma of the mammary glands and uterine fibroids, atherosclerosis of vessels of lower extremities and many others without surgery and without the use of medication

The invention relates to medical equipment and can be used for magnetic therapy, and to examine the effect of variable low frequency of vortex magnetic fields on biological objects

The invention relates to medicine and intended for the introduction of ions of metallic silver

The invention relates to medical equipment, namely, magnetic therapy, and can be used in the treatment of liver cirrhosis, hepatitis, pancreatitis, peptic ulcer disease of stomach and duodenal ulcer twelve, for painless crushing and output concretions from the liver, gallbladder, kidneys, pancreas and bladder, prostatic hypertrophy, in the treatment of mastitis and fibroadenoma of the mammary glands, atherosclerosis of vessels of lower extremities, radiculitis, osteochondrosis
The invention relates to medicine, in particular to urology
The invention relates to methods of magnetic therapy

The invention relates to medicine, namely to transplantation, and is intended for the treatment of burn wounds

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves building tunnel to posterior eyeball pole in inferoexterior and superexterior quadrants. The tunnel is used for implanting flexible polymer magnetolaser implant to the place, the subretinal neovascular membrane is localized. The implant has a permanent magnet shaped as a cut ring and is provided with drug delivery system and a short focus scattering lens of laser radiator connected to light guide. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 5-7 mTesla units intensity. It is arranged with its north pole turned towards sclera at the place of the subretinal neovascular membrane projection with extrascleral arrangement of laser radiator lens membrane being provided in the subretinal neovascular membrane projection area. The other implant end is sutured to sclera 5-6 mm far from the limb via holes made in advance. The implant is covered with conjunctiva and retention sutures are placed thereon. Light guide and drug supply system lead is attached to temple with any known method applied. Drugs are supplied via the implant drug supply system in retrobulbary way in any order. Triombrast is given in the amount of 0,4-0,6 ml and dexamethasone or dexone in the amount of 0,4-0,6 ml during 3-4 days every 12 h. 0.1-1% aqueous solution of khlorin is intravenously introduced at the third-fourth day after setting the implant as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, at a bolus dose of 0.8-1.1 mg/kg. Visual control of subretinal neovascular membrane cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the subretinal neovascular membrane with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at general dose of 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the subretinal neovascular membrane via laser light guide and implant lens, repeated laser irradiation of the subretinal neovascular membrane is carried out with radiation dose of 30-60 J/cm2.

EFFECT: accelerated subretinal edema and hemorrhages resorption; regression and obliteration of the subretinal neovascular membrane; prolonged vision function stabilization.

6 cl

FIELD: medicine.

SUBSTANCE: method involves carrying out transpupillary laser avascular zones coagulation. Taurin is dropped into conjunctival cavity at a dose of 1-2 drops into the eye under treatment 5-6 times a day during 7-10 days. 0.02% Histochrome solution is dropped into conjunctival cavity at a dose of 2 drops into the eye under treatment 5-6 times a day during 7-10 days. 0.02% Histochrome solution or 0.02% Emoxipin solution or 1% Retinalamine solution in the amount of 0.4-0.6 ml once a day is parabulbary introduced as antioxidant during 7-10 days. Magnetic stimulation course is applied on the background of conservative therapy to orbital or temporal head region of prematurely born child in any succession using external rotating permanent magnetic field of 0.15-0.40 mTesla units intensity. Periodicity of external magnetic field action is selected to be 1-2 times per day with external action duration being equal to 3-5 min per 1 session during 10 days with magnetic field being 15-30 cm far from orbital or temporal head region of prematurely born child. External permanent magnetic field rotating at constant or variable speed is applied for carrying out magnetic stimulation treatment. Repeated conservative therapy and magnetic stimulation treatment with external rotating permanent magnetic field is additionally applied in 1-3 months. The number of repeated courses is equal to 1-3.

EFFECT: enhanced effectiveness of prophylactic treatment; prevented severe disease forms progress; released retina edema; improved blood circulation in avascular zones.

3 cl

FIELD: medicine.

SUBSTANCE: method involves carrying out transpupillary laser coagulation of central avascular zones and transscleral cryocoagulation of peripheral avascular retina zones. 3-4 mm long incisions in conjunctiva and Tenon's capsule are done between sclera and Tenon's capsule in perpendicular to limbus 3-4 mm far from it. Tunnel is built in projection zone of an avascular retina zone between sclera and Tenon's capsule in parallel to the limbus on both sides of the incision. Flexible polymer magnetic implant is extrasclerally introduced into the tunnel in projection zone of an avascular retina zone. The implant has its own permanent magnetic field with magnetic poles alternating on each of sides and permanent magnetic field intensity of 0.5-1.0 mTesla units. The implant is sutured with one of its ends to sclera, and suture is placed on conjunctiva, and anti-oxidant therapy is applied. Magnetic stimulation therapy course is applied 3-4 weeks later. The course combines actions of permanent magnetic field produced by extrasclerally arranged magnetic implant and external rotating permanent magnetic field of 0.30-0.40 mTesla units intensity. Periodicity of external magnetic field action is selected to be 1-2 times per day with external action duration being equal to 3-5 min per 1 session during 10 days. The extrasclerally arranged flexible polymer magnetic implant is removed when treatment course is over. The flexible polymer magnetic implant is manufactured from biologically stable polymer material like one on polypropylene, polyester or polyethylene basis having permanent magnet material powder particles uniformly distributed therein. Magnetic material particles are of samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen base.

EFFECT: enhanced effectiveness of prophylactic treatment; prevented severe disease forms progress; released retina edema.

6 cl

FIELD: medicine.

SUBSTANCE: method involves carrying out vitrectomy with posterior hyaline membrane being removed. Retinotomy is carried out with subretinal neovascular complex being removed. Autogenous pigment retinal epithelium is subretinally introduced through retinotomy area as stratum or suspension. The intravitreous tamponade is carried out with perfluororganic compound substituted with air next to it. Flexible polymer magnetolaser implant having ring-shaped magnet with axial permanent magnetic field magnetization of 3-7 mTesla units is extrasclerally mounted into tunnel built between sclera and Tenon's capsule in macular area projection zone. The implant is turned with S pole towards transplanted cells so that laser radiation-emitting lens is arranged in their projection zone. Implant light guide is sutured to sclera 5-6 mm far from limb. The implant is covered with conjunctiva. Light guide outlet is attached to temple. The introduced cells are treated via laser light guide and implant lens with divergent continuous laser radiation. The magnetic implant is removed after having finished the treatment course and sutures are placed on conjunctiva.

EFFECT: enhanced effectiveness of treatment.

FIELD: medical engineering.

SUBSTANCE: method involves acting in turn with ultrasonic and magnetic field with switch frequency of 10 to 160 Hz. Ultrasonic field intensity is set below cavitation threshold and ultrasonic oscillation frequency being equal to liquid acoustic relaxation frequency. Magnetic field induction being selected within the limits of 30-50 mTesla units.

EFFECT: enhanced effectiveness of liquid activation; reduced power consumption.

1 dwg

FIELD: medicine, surgery.

SUBSTANCE: the present innovation deals with operative interference followed by the impact with magnetolaser infrared radiation of 80 Hz frequency per 30 sec or 2-4 fields and with direct magnetic field at the value of magnetic induction being 25-50 mTl for 10-20 min successively. At first, one should affect postoperational area, the - reflexogenic area at one's foot, daily for 8-12 d. Since the 9th - 13th d one should affect with single direct magnetic field with the value of magnetic induction being 25-50 mTl for 10-20 min successively. At first, one should affect postoperational area, then - reflexogenic area at one's foot for 10 -12 d. The innovation decreases the frequency of postoperational complications.

EFFECT: shortened terms of therapy.

2 ex

Medical applicator // 2269368

FIELD: medical engineering.

SUBSTANCE: device has metal casing having permanent magnet inside. Electrode is outside of the casing and connected to electric current source. The second electrode, manufactured from non-magnetic material having cavity, is inside of the casing. Permanent magnetic is mounted in the cavity. Substance like mineral solution or plant oil is placed between the electrodes. Dielectric bushing is mounted in the casing for insulating electrodes and substance from the casing. Electric current supply source is mounted with one of its contacts on the first electrode and with its second electrode having ironwork fault. One of applicator embodiments has spring placed between electric current supply source and casing. Another version has electrode mounted outside of the casing. It is manufactured from nonferrous metal having silver coating.

EFFECT: wide range of functional applications.

3 cl, 1 dwg

FIELD: medicine.

SUBSTANCE: method involves rectally exposing prostate projection zone to red, infrared radiation, magnetic field and magnetic therapy is applied to sacral region, pubis and perineum. Magnetized sapropelic tampon is introduced into the rectum after applying combined rectal treatment. Tampon volume is equal to 140-160 ml and hold for 30-40 min under temperature of 37-38°C and magnetic therapy is applied to sacral region, pubis and perineum region.

EFFECT: wide range of therapeutic applications.

Up!